Phase 2 Peripheral Arterial Disease Trial, Recruiting NCT06399809 Sponsor: Northwestern University Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Phase 2 Peripheral Arterial Disease Trial, Recruiting

NCT06399809
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 50 years of age or older
  • You have been diagnosed with peripheral artery disease (PAD), which is a condition where the arteries supplying blood to your legs are narrowed or blocked
  • Your PAD has been confirmed by a specific blood pressure measurement in your ankle or toe, or by an imaging test showing a significant blockage in a leg artery
  • You may also qualify if your ankle blood pressure reading is in a borderline range but drops significantly after a simple heel-rise exercise test

Who may not be able to join:

  • You have had an amputation of part or all of either leg
  • You have very severe PAD with extremely poor blood flow to your limbs (confirm with trial site)
  • You use a wheelchair or need a walker to get around
  • Your ability to walk is mainly limited by a condition other than PAD
  • You currently have an open sore or ulcer on the bottom of your foot
  • You are unable to complete a required warm-up period before the trial officially begins
  • You have major surgery, a heart procedure, or a leg artery procedure planned in the next five months
  • You have had major surgery, a heart procedure, a leg artery procedure, or a serious heart event in the past three months
  • You have a serious medical condition such as a lung disease requiring oxygen, Parkinson's disease, a life expectancy of less than six months, or cancer treated in the past two years (some exceptions may apply — confirm with trial site)
  • You scored below a certain level on a standard memory and thinking test (confirm with trial site)
  • You are allergic to fisetin (a natural supplement being studied in this trial)
  • You are currently taking fisetin or have taken it in the past three months
  • You do not speak English
  • You are currently in another clinical trial or finished one in the past three months (some exceptions may apply depending on the type of trial — confirm with trial site)
  • You have a visual impairment that affects your ability to walk
  • You are unable to walk at least 500 feet or walk more than 1,600 feet in a six-minute walking test
  • You have taken part in a supervised treadmill exercise program in the past three months
  • You are unwilling to have a small fat tissue sample taken (though this requirement may be flexible — confirm with trial site)
  • You are a woman who has not yet gone through menopause (defined as having had no menstrual period for the past 12 months)
  • Your blood test results show your liver is not functioning within an acceptable range (confirm with trial site)
  • Your blood test results show problems with red blood cells, white blood cells, or platelets outside of acceptable ranges (confirm with trial site)
  • Your kidneys are not functioning well enough based on a specific blood test (confirm with trial site)
  • Your blood sugar control is very poor, as shown by a specific diabetes test result (confirm with trial site)
  • You are HIV positive, or you have active hepatitis B or hepatitis C with a high viral load
  • You take a blood-thinning medication called warfarin, or certain other medications that interact with the study drug, unless those medications can safely be paused around the time of each dose (confirm with trial site)
  • Your body mass index (BMI) is above 43
  • The trial team decides, based on their medical judgment, that the trial may not be safe or appropriate for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 312-503-6419

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
30 September 2024
Est. completion
1 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Six-minute Walk Distance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov